Natco Pharma Ltd
NSE: NATCOPHARM BSE: 524816
₹959.20
(2.25%)
Sat, 21 Mar 2026, 01:15 pm
Market Cap171.56B
PE Ratio11.03
Dividend0.52
Health Technology
Pharmaceuticals: Major
24.5KNatco Pharma Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are well covered by earnings (3.8x coverage).
- Dividends after 3 years are expected to be thoroughly covered by earnings (9.2x coverage).
- NATCO Pharma's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- NATCO Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Cash flow for NATCO Pharma is expected to increase by more than 50% in 2 years time.
- NATCO Pharma's earnings are expected to grow significantly at over 20% yearly.
- NATCO Pharma's earnings growth is expected to exceed the India market average.
- NATCO Pharma's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- NATCO Pharma's earnings are expected to exceed the low risk growth rate next year.
- NATCO Pharma's earnings are expected to increase by more than the low risk growth rate in 3 years time.
- NATCO Pharma is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
- Performance (ROE) is expected to be above the current IN Pharmaceuticals industry average.
- An improvement in NATCO Pharma's performance (ROE) is expected over the next 3 years.
- NATCO Pharma's revenue growth is expected to exceed the India market average.
- NATCO Pharma's net income is expected to increase but not above the 50% threshold in 2 years time.
- NATCO Pharma's revenue is expected to increase but not above the 50% threshold in 2 years time.
- NATCO Pharma's revenue is expected to grow by 15.7% yearly, however this is not considered high growth (20% yearly).
health
- NATCO Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- NATCO Pharma is profitable, therefore cash runway is not a concern.
- NATCO Pharma is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (53.1%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 7.8x debt.
- NATCO Pharma's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (27.8% vs 8.2% today).
- NATCO Pharma earns more interest than it pays, coverage of interest payments is not a concern.
- NATCO Pharma's level of debt (8.2%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the NATCO Pharma board of directors is about average.
- Rajeev's remuneration is lower than average for companies of similar size in India.
- Rajeev's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the NATCO Pharma management team is over 5 years, this suggests they are a seasoned and experienced team.
misc
- NATCO Pharma has significant price volatility in the past 3 months.
past
- NATCO Pharma has delivered over 20% year on year earnings growth in the past 5 years.
- NATCO Pharma used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- NATCO Pharma's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- NATCO Pharma's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- NATCO Pharma has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- NATCO Pharma's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- 524816 outperformed the Market in India which returned -14.5% over the past year.
- BSE:524816 is up 9.5% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524816 is up 9.5% outperforming the market in India which returned 8% over the past month.
- NATCO Pharma's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- NATCO Pharma's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- NATCO Pharma is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- NATCO Pharma is poor value based on expected growth next year.
- NATCO Pharma is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- NATCO Pharma is overvalued based on earnings compared to the India market.
- 524816 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800